These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
657 related articles for article (PubMed ID: 31732485)
1. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485 [TBL] [Abstract][Full Text] [Related]
2. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076 [TBL] [Abstract][Full Text] [Related]
3. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Cevik M; Thompson LC; Upton C; Rolla VC; Malahleha M; Mmbaga B; Ngubane N; Abu Bakar Z; Rassool M; Variava E; Dawson R; Staples S; Lalloo U; Louw C; Conradie F; Eristavi M; Samoilova A; Skornyakov SN; Ntinginya NE; Haraka F; Praygod G; Mayanja-Kizza H; Caoili J; Balanag V; Dalcolmo MP; McHugh T; Hunt R; Solanki P; Bateson A; Crook AM; Fabiane S; Timm J; Sun E; Spigelman M; Sloan DJ; Gillespie SH; Lancet Infect Dis; 2024 Sep; 24(9):1003-1014. PubMed ID: 38768617 [TBL] [Abstract][Full Text] [Related]
4. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Moodliar R; Dodd M; Solodovnikova V; Liverko I; Rajaram S; Rassool M; McHugh T; Spigelman M; Moore DA; Ritmeijer K; du Cros P; Fielding K; Lancet Respir Med; 2024 Feb; 12(2):117-128. PubMed ID: 37980911 [TBL] [Abstract][Full Text] [Related]
9. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis. Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771 [TBL] [Abstract][Full Text] [Related]
10. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis. Berry C; du Cros P; Fielding K; Gajewski S; Kazounis E; McHugh TD; Merle C; Motta I; Moore DAJ; Nyang'wa BT Trials; 2022 Jun; 23(1):484. PubMed ID: 35698158 [TBL] [Abstract][Full Text] [Related]
11. Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy. Dawson R; Diacon AH; Takuva S; Liu Y; Zheng B; Karwe V; Hafkin J Trials; 2024 Jan; 25(1):70. PubMed ID: 38243296 [TBL] [Abstract][Full Text] [Related]
12. Pretomanid for tuberculosis: a systematic review. Gils T; Lynen L; de Jong BC; Van Deun A; Decroo T Clin Microbiol Infect; 2022 Jan; 28(1):31-42. PubMed ID: 34400340 [TBL] [Abstract][Full Text] [Related]
13. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis. Xu J; Li SY; Almeida DV; Tasneen R; Barnes-Boyle K; Converse PJ; Upton AM; Mdluli K; Fotouhi N; Nuermberger EL Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833432 [TBL] [Abstract][Full Text] [Related]
14. Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial. Manyazewal T; Woldeamanuel Y; Holland DP; Fekadu A; Blumberg HM; Marconi VC Trials; 2020 May; 21(1):383. PubMed ID: 32370774 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. von Groote-Bidlingmaier F; Patientia R; Sanchez E; Balanag V; Ticona E; Segura P; Cadena E; Yu C; Cirule A; Lizarbe V; Davidaviciene E; Domente L; Variava E; Caoili J; Danilovits M; Bielskiene V; Staples S; Hittel N; Petersen C; Wells C; Hafkin J; Geiter LJ; Gupta R Lancet Respir Med; 2019 Mar; 7(3):249-259. PubMed ID: 30630778 [TBL] [Abstract][Full Text] [Related]
16. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149 [TBL] [Abstract][Full Text] [Related]
17. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Conde MB; Efron A; Loredo C; De Souza GR; Graça NP; Cezar MC; Ram M; Chaudhary MA; Bishai WR; Kritski AL; Chaisson RE Lancet; 2009 Apr; 373(9670):1183-9. PubMed ID: 19345831 [TBL] [Abstract][Full Text] [Related]
18. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial. Lee JK; Lee JY; Kim DK; Yoon HI; Jeong I; Heo EY; Park YS; Jo YS; Lee JH; Park SS; Park JS; Kim J; Lee SM; Joh JS; Lee CH; Lee J; Choi SM; Park JH; Lee SH; Cho YJ; Lee YJ; Kim SJ; Kwak N; Hwang YR; Kim H; Ki J; Lim JN; Choi HS; Lee M; Song T; Kim HS; Han J; Ahn H; Hahn S; Yim JJ Lancet Infect Dis; 2019 Jan; 19(1):46-55. PubMed ID: 30477961 [TBL] [Abstract][Full Text] [Related]
19. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis]. Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568 [TBL] [Abstract][Full Text] [Related]